← Back to all protocols
20

Thromboembolic Disease in Pregnancy & the PuerperiumObstetric

πŸ“‹ Guideline currency β€” checked 2026-09-28
  • NICE β€” NG158 (Venous thromboembolic diseases: diagnosis, management and thrombophilia testing) explicitly excludes pregnant women from its scope and defers to specialist obstetric guidance β€” it is not used in this protocol.
  • RCOG Green-top Guideline No. 37b β€” Thrombosis and Embolism during Pregnancy and the Puerperium: Acute Management. Third edition, April 2015 (RCOG's guideline listing shows a March 2022 site update; no newer full edition was identified at the time this protocol was checked). Covers diagnosis and acute management β€” the main source for this protocol.
  • RCOG Green-top Guideline No. 37a β€” Reducing the Risk of Thrombosis and Embolism during Pregnancy and the Puerperium. Covers prevention/thromboprophylaxis (see section 12).
  • RCOG interim position statement (September 2026): aligns Green-top 37a with the NHS England Maternal Care Bundle β€” adds a national VTE self-assessment questionnaire at first pregnancy contact and a standalone BMI >50 kg/mΒ² trigger for thromboprophylaxis, with revised weight-banded prophylactic LMWH doses. A full revised edition of 37a is expected Spring 2027; until then, follow 37a with these amendments. Verify exact current doses against the live RCOG/NHS England documents before relying on them, as this is an evolving interim position.
  • Where NICE and RCOG differ: they do not directly conflict on management β€” NICE NG158 simply does not apply in pregnancy and defers entirely to RCOG, so Green-top 37a/37b govern this whole protocol.

1 Β· At a Glance

  • Pregnancy or postpartum (puerperium) + suspected VTE β†’ investigate urgently and involve obstetrics Β± haematology/medicine early.
  • In clinically suspected DVT or PE, start therapeutic-dose LMWH immediately (weight-based, section 7) before imaging confirms the diagnosis β€” unless anticoagulation is strongly contraindicated. Do not wait for a scan.
  • Suspected DVT β†’ compression duplex ultrasound is the primary test (section 4).
  • Suspected PE β†’ ECG + CXR first; if DVT symptoms are present, ultrasound may confirm VTE and avoid chest imaging; otherwise V/Q scan or CTPA depending on the CXR and local availability (section 5).
  • D-dimer has no role in diagnosing VTE in pregnancy β€” do not use it to exclude VTE here; this differs from standard non-pregnant pathways (section 6).

2 Β· Clinical Presentation β€” DVT

  • Unilateral leg swelling β€” a circumference difference is more informative than swelling alone
  • Leg pain, tenderness, or calf/thigh discomfort
  • Lower abdominal, back or buttock pain can reflect extension into the iliac/pelvic veins β€” consider iliac vein thrombosis if the whole limb is swollen
  • Pregnancy itself commonly causes bilateral leg swelling/oedema, especially in the third trimester β€” this overlaps with DVT symptoms; unilateral asymmetry is the key discriminator
  • Low-grade pyrexia and a mild leucocytosis can occur with VTE and do not exclude it

2 Β· Clinical Presentation β€” PE

  • Sudden or unexplained dyspnoea
  • Pleuritic chest pain
  • Tachycardia, hypoxia
  • Haemoptysis
  • Syncope, pre-syncope, or collapse
  • Coexisting symptoms/signs of DVT
  • Severe/unstable presentation: collapse, shock, severe hypoxaemia, cardiac arrest β€” treat as massive PE (section 9)

3 Β· Immediate Assessment

  • ABCDE approach
  • Maternal vital signs and oxygen saturation
  • ECG
  • IV access; bloods where indicated (FBC, coagulation screen, U&E, LFTs β€” see section 7, taken before anticoagulation if possible but do not delay treatment)
  • Assess haemodynamic stability
  • Consider fetal assessment according to gestational age and local obstetric practice
  • Early senior/obstetric involvement when appropriate
  • Haemodynamically UNSTABLE suspected PE (collapse, shock, severe hypoxaemia, cardiac arrest) β†’ this is a medical emergency; go straight to section 9 (Massive/high-risk PE)
  • Haemodynamically STABLE suspected PE β†’ proceed via the stepwise diagnostic pathway in section 5

4 Β· Suspected DVT β€” Diagnosis

  • Compression duplex ultrasound is the primary diagnostic test wherever DVT is clinically suspected
  • Ultrasound positive β†’ continue therapeutic LMWH; diagnosis confirmed
  • Ultrasound negative + LOW clinical suspicion β†’ anticoagulation can be discontinued
  • Ultrasound negative + HIGH clinical suspicion β†’ discontinue anticoagulant treatment but repeat the ultrasound on days 3 and 7; if repeat testing is negative, no further treatment is required; if repeat testing confirms DVT, recommence and continue anticoagulation
  • Suspected iliac vein thrombosis (back/buttock pain, whole-limb swelling): consider Doppler ultrasound of the iliac vein, magnetic resonance venography, or conventional contrast venography
  • Continue therapeutic LMWH throughout this diagnostic process unless treatment is strongly contraindicated
  • Do NOT apply the standard non-pregnant DVT/Wells pathway automatically β€” D-dimer and pretest probability tools are not validated in pregnancy (section 6)

5 Β· Suspected PE β€” Diagnosis

  • Initial investigations: ECG, chest X-ray (CXR), routine bloods (FBC, coagulation screen, U&E, LFTs), and assessment for DVT symptoms/signs
  • If DVT symptoms/signs are present: perform compression duplex ultrasound. If it confirms DVT, no further investigation for PE is necessary β€” continue treatment for VTE
  • If no DVT symptoms, or ultrasound is negative, chest imaging is needed: CXR normal β†’ ventilation/perfusion (V/Q) scan (the ventilation component can often be omitted, reducing fetal radiation dose further); CXR abnormal with clinical suspicion of PE β†’ CTPA is preferred over V/Q
  • Radiation trade-off (discuss with the woman where feasible, and obtain informed consent before either test): CTPA gives a low fetal radiation dose but a comparatively higher maternal breast radiation dose (small increased lifetime breast cancer risk); V/Q gives a lower maternal breast dose but a slightly higher theoretical childhood cancer risk to the fetus β€” in both cases the absolute risk is very small
  • Neither CTPA nor V/Q is universally preferred β€” the choice depends on CXR findings, clinical circumstances, local availability, and these radiation considerations
  • If initial imaging is normal but clinical suspicion of PE remains: carry out alternative or repeat testing; continue anticoagulant treatment until PE is definitively excluded

6 Β· D-dimer in Pregnancy

  • D-dimer testing should NOT be performed in the investigation of acute VTE in pregnancy, per current RCOG guidance.
  • Reason: D-dimer rises progressively through normal pregnancy and is frequently 'abnormal' by term and postpartum even without VTE β€” a positive result is not diagnostic, and no validated pregnancy-specific cut-off exists.
  • Pretest probability scoring tools (e.g. Wells) are also not currently validated for use in pregnancy β€” there is no evidence to support their use here.
  • This is a genuine divergence from standard non-pregnant VTE pathways, but note NICE NG158 (which underpins the non-pregnant D-dimer/Wells pathway) explicitly excludes pregnancy from its scope in the first place β€” so there is no direct NICE-vs-RCOG conflict to reconcile, RCOG simply governs.

7 Β· Anticoagulation While Awaiting Diagnosis

  • Start immediately: in any woman with clinically suspected DVT or PE, begin therapeutic-dose LMWH before the diagnosis is confirmed by objective testing, unless treatment is strongly contraindicated β€” continue until VTE is excluded
  • LMWH is the preferred anticoagulant. Dose by booking or early-pregnancy weight β€” not current weight:
  • Enoxaparin β€” <50kg: 40mg BD or 60mg OD Β· 50–69kg: 60mg BD or 90mg OD Β· 70–89kg: 80mg BD or 120mg OD Β· 90–109kg: 100mg BD or 150mg OD Β· 110–125kg: 120mg BD or 180mg OD Β· >125kg: discuss with haematology
  • Dalteparin β€” <50kg: 5000iu BD or 10,000iu OD Β· 50–69kg: 6000iu BD or 12,000iu OD Β· 70–89kg: 8000iu BD or 16,000iu OD Β· 90–109kg: 10,000iu BD or 20,000iu OD Β· 110–125kg: 12,000iu BD or 24,000iu OD Β· >125kg: discuss with haematology
  • Tinzaparin β€” 175 units/kg once daily at all weights, based on booking/early-pregnancy weight
  • There is insufficient evidence to prefer once-daily over twice-daily dosing β€” follow your local guideline for which regimen to use
  • Renal impairment: use lower doses if creatinine clearance is below 30 mL/min (enoxaparin/dalteparin) or below 20 mL/min (tinzaparin) β€” discuss with haematology
  • Monitoring: routine peak anti-Xa monitoring is not required, except at extremes of body weight (<50kg or β‰₯90kg) or with other complicating factors (e.g. renal impairment, recurrent VTE) β€” target peak anti-Xa 0.5–1.2 u/mL, taken 3 hours post-injection. Routine platelet count monitoring is not needed on LMWH; if postoperative and on unfractionated heparin, check platelets every 2–3 days from days 4–14
  • Baseline bloods before starting anticoagulation: full blood count, coagulation screen, urea & electrolytes, liver function tests. Thrombophilia screening is NOT recommended before treatment β€” pregnancy itself alters the results
  • Do not use vitamin K antagonists (e.g. warfarin) antenatally β€” teratogenic and fetal bleeding risk. Avoid DOACs/NOACs in pregnancy β€” they cross the placenta and lack safety data
  • Heparin allergy or HIT: consider fondaparinux, danaparoid, argatroban or r-hirudin under specialist/haematology advice β€” none of these are licensed for use in pregnancy

8 Β· Confirmed DVT β€” Management

  • Continue therapeutic-dose LMWH (dosing above) for the remainder of the pregnancy and for at least 6 weeks postnatally, until at least 3 months of treatment has been given in total
  • Elevate the leg and apply a graduated elastic compression stocking in the initial management to reduce oedema; encourage early mobilisation with compression β€” bed rest is not required or beneficial
  • Consider a temporary inferior vena cava (IVC) filter, particularly peripartum, for iliac vein DVT or recurrent PE despite adequate anticoagulation
  • Teach the woman to self-inject and arrange safe disposal of needles/syringes
  • Postpartum considerations and follow-up: postnatal review at an obstetric medicine or joint obstetric–haematology clinic where possible; monitor platelets/anti-Xa only if indicated (see section 7)
  • Specialist involvement: obstetrics, and haematology or obstetric medicine for ongoing management

9 Β· Confirmed PE

  • Stable PE: continue therapeutic LMWH as above (remainder of pregnancy + β‰₯6 weeks postnatally, β‰₯3 months total); risk-stratify for outpatient vs admission per local practice; graduated compression stockings if DVT coexists
  • Massive / high-risk / unstable PE β€” collapse, shock, severe hypoxaemia, RV dysfunction on echo β€” is a medical emergency:
  • Resuscitation: assessed immediately by a multidisciplinary team of experienced clinicians including the on-call consultant obstetrician, senior physicians, haematology and radiology. Standard ABC resuscitation; if cardiac arrest occurs, start CPR with manual left-lateral uterine displacement/tilt, and perform a perimortem caesarean section by 5 minutes if resuscitation is unsuccessful and the pregnancy is beyond 20 weeks
  • Arrange an urgent portable echocardiogram or CTPA within 1 hour of presentation
  • Anticoagulation: IV unfractionated heparin is the preferred initial treatment in massive PE with cardiovascular compromise β€” loading dose 80 units/kg IV, then a continuous infusion at 18 units/kg/hour, adjusted against the APTT ratio (target 1.5–2.5Γ— control; check 4–6h after the loading dose, 6h after any dose change, then at least daily once in range) using your local nomogram
  • Obstetric, critical care and cardiology/respiratory/haematology involvement throughout, per local massive-PE pathway
  • Thrombolysis: an EXCEPTIONAL treatment reserved for life-threatening PE with haemodynamic compromise β€” not routine treatment, because anticoagulation alone will not relieve the obstruction. If thrombolysis is given, omit the heparin loading dose and start the infusion at 18 units/kg/hour afterward. Main risk is maternal and fetal bleeding
  • If not suitable for thrombolysis, or moribund: urgent discussion with cardiothoracic surgery regarding thoracotomy/surgical embolectomy
  • Management (heparin vs thrombolysis vs surgery) is individualised by the senior multidisciplinary team β€” this is not protocol-driven

10 Β· LMWH + Labour / Delivery / Neuraxial Anaesthesia

  • Advise the woman: once in established labour, or if she thinks she is in labour, she should not inject any further LMWH
  • Planned delivery (elective caesarean or induction of labour): stop therapeutic LMWH 24 hours before the planned delivery
  • Neuraxial (spinal/epidural) anaesthesia: should not be performed until at least 24 hours after the last dose of therapeutic LMWH
  • After a neuraxial block: do not give LMWH for at least 4 hours after spinal anaesthesia or after epidural catheter removal, and do not remove an epidural catheter within 12 hours of the most recent LMWH injection
  • Labour starts unexpectedly shortly after an LMWH dose: bleeding complications are uncommon, but monitor closely and involve senior obstetric/anaesthetic input; if regional anaesthesia is being considered, coordinate timing with anaesthetics as above
  • At term: if VTE occurs close to delivery, consider switching to IV unfractionated heparin, which is easier to manipulate and reverse β€” discontinue subcutaneous unfractionated heparin 12 hours, and IV unfractionated heparin 6 hours, before induction or regional anaesthesia
  • Caesarean section on therapeutic LMWH: consider wound drains (abdominal and rectus sheath) and close the skin with interrupted sutures to allow drainage of any haematoma; coordinate the timing of postoperative thromboprophylactic and treatment-dose LMWH with obstetrics, anaesthesia and haematology
  • High bleeding risk: use IV unfractionated heparin (short half-life, reversible with protamine sulfate) until the bleeding risk factors have resolved
  • There is no single blanket interval that applies to every LMWH dose or regimen β€” always confirm timing against the specific dose given and your local anaesthetic protocol; coordinate every delivery plan with obstetrics and anaesthesia in advance

11 Β· Postpartum / Puerperium

  • Continue therapeutic anticoagulation for the duration of the pregnancy AND for at least 6 weeks postnatally, to a total of at least 3 months of treatment; reassess the ongoing risk of thrombosis before stopping
  • Choice of anticoagulant postpartum: continue LMWH, or switch to warfarin β€” discuss the need for regular blood test monitoring with warfarin, particularly in the first 10 days of treatment
  • If starting warfarin: avoid until at least the 5th postnatal day (later if increased postpartum haemorrhage risk); overlap with heparin until the INR is >2.0 for at least 24 hours; dose using a haematology-agreed nomogram, with INR checked on day 2 of warfarin treatment
  • Breastfeeding: neither LMWH, unfractionated heparin, nor warfarin is contraindicated
  • Follow-up: postnatal review, ideally at an obstetric medicine or joint obstetric–haematology clinic
  • Recurrence risk / patient education: safety-net on symptoms of recurrent VTE and of post-thrombotic syndrome (chronic leg swelling, pain, skin changes); discuss thromboprophylaxis needs for any future pregnancy at follow-up
  • This acute treatment pathway is separate from VTE prevention/thromboprophylaxis in women who have NOT had a VTE β€” see section 12

12 Β· Prevention of VTE in Pregnancy and Postpartum (Thromboprophylaxis)

  • This section is prevention for at-risk women who have NOT had a confirmed VTE β€” do not confuse it with the treatment doses in sections 7–11, which apply once VTE is suspected or confirmed.
  • Interim update β€” RCOG position statement, September 2026: RCOG has issued interim clinical guidance aligning Green-top Guideline 37a with the NHS England Maternal Care Bundle, pending a full revised edition of 37a expected Spring 2027. Follow current 37a with these amendments:
  • All pregnant women are now screened for VTE risk at first contact with maternity care (from a positive pregnancy test), using a national self-assessment questionnaire
  • BMI >50 kg/mΒ² is now, on its own, a trigger for thromboprophylaxis throughout pregnancy and for 6 weeks postpartum β€” previously this sat within a broader weighted risk score
  • High-risk women (including a previous VTE, hyperemesis gravidarum with dehydration/immobility, or BMI >50) should be started on prophylactic-dose LMWH within 72 hours of risk identification, with follow-up in secondary care within 4 weeks to reassess risk
  • Indicative Maternal Care Bundle prophylactic LMWH doses (once daily): enoxaparin 40mg (β‰₯100kg: 60mg); tinzaparin 3500 units (β‰₯100kg: 4500 units); dalteparin 5000 units (β‰₯100kg: 7500 units) β€” verify the exact current dose against the live RCOG/NHS England Maternal Care Bundle documents before using, as this is an evolving interim position, and note these are prevention doses, not treatment doses
  • Other established risk factors from standing Green-top 37a remain relevant alongside the BMI-50 trigger: previous VTE, thrombophilia, obesity, age >35, parity β‰₯3, smoking, gross varicose veins, current systemic infection, immobility, pre-eclampsia, multiple pregnancy, IVF pregnancy, caesarean section (especially emergency), prolonged labour, mid-cavity/rotational operative delivery, and postpartum haemorrhage >1L or transfusion
  • Duration follows the individual risk assessment β€” typically continued to delivery antenatally, and for 6 weeks postnatally for higher-risk indications (shorter courses apply to some lower-risk indications) β€” follow your local protocol based on current 37a

13 Β· Important Differential Diagnoses

  • For suspected PE: pneumonia, pneumothorax, acute coronary syndrome, aortic pathology, peripartum cardiomyopathy, asthma, anaemia, sepsis, and β€” where clinically relevant β€” amniotic fluid embolism
  • For suspected DVT: cellulitis, musculoskeletal pain, superficial thrombophlebitis, compression from the gravid uterus, a ruptured Baker's cyst, and other causes of unilateral leg swelling

14 Β· Red Flags β€” Immediate Senior / Obstetric / Critical Care Involvement

  • Hypotension or shock
  • Severe hypoxaemia
  • Syncope or collapse
  • Cardiac arrest
  • Severe respiratory distress
  • Evidence of right-heart strain or acute RV failure
  • Massive PE
  • Major bleeding, or a contraindication to anticoagulation in a woman who needs it
  • Any other situation requiring urgent multidisciplinary management

15 Β· Quick ED Flowchart

Pregnant / postpartum patient with suspected VTE
↓
Suspected DVT? β†’ compression ultrasound pathway (section 4)
↓
Suspected PE? β†’ assess stability β†’ ECG/CXR β†’ DVT symptoms present? β†’ appropriate imaging pathway (section 5)
↓
Start/continue therapeutic LMWH when indicated, throughout work-up
↓
Confirmed or excluded
↓
Appropriate specialist management and follow-up (sections 8–12)
← Back to all protocols